FERRITIN NANOPARTICLE IN BREAST CANCER TREATMENT

Ferreira, D. A. (Universidade de Brasília), Guerrini, A. (Università degli Studi di Firenze), Farias, G. R. (Universidade de Brasília), Leite, G. C. P. (Universidade Federal de Goiás), Vaz, M. (Universidade Federal Fluminense), Novak, M. (Universidade Fed

Universidade de BrasíliaConsidering magnetohyperthermia (MHT) as a promising therapy for cancer treatments due to the advantages over conventional therapies, the aim of this study was to characterize the nanoparticles of a new nanoplatform system using a magnetite nanoparticle encapsulated in human ferritin cages (NP-HFt) and investigate its biocompatibility and efficacy for the treatment of breast cancer. To characterize the nanoparticle, Transmission Electronic Microscopy, Atomic Force Microscopy and Dynamic Light Scattering were performed. In addition, five different concentrations of the nanoparticle were exposed to an alternating magnetic field to evaluate which concentration reached the best temperature for MHT. The MTT viability cell assay was performed to evaluate the toxicity of the NP-HFT. Furthermore, to verify the internalization of the nanoparticle, Fluorescence Microscopy was carried using several cell lines. NP-HFt sample was administrated to Ehrlich tumor bearing Swiss mice subsequently exposed to an alternating magnetic field following previous protocols of MHT. Characterization data showed that the average diameter of the nanoparticle is 13.5 nm with monodisperse features. Magnetic behavior studies of the nanoparticle showed that NP-HFt has a superparamagnetic property at room temperature. It was evaluated that the concentration of 1, 0,8 and 0,6 mg Fe had reached the desired temperature of 43ºC. The MTT assay revealed that the NP-HFt was not toxic in the concentrations between 0,001 to 0,3 mg Fe/ml for colon adenocarcinoma cell line after 1.5h and 48h of incubation. The fluorescence microscopy analysis showed that different cancer cell lines are able to internalize the nanoparticle after 1h of incubation. The efficacy of NP-HFt sample to reduce the tumor size is currently under investigation. Results suggest that the NP-HFt presents the appropriated physical and biological characteristics for in vivo tests and thus a great potential to be used as a nanocomposite associated with magnetohyperthermia for breast cancer treatment.breast cancer, magnetohyperthermia

Return